Pembrolizumab/Lenvatinib Combo Tops Week in Review
Top news of the day from across the health care landscape.
5. NASP 2019: A Doctor's Perspective on Specialty Pharmacy
The annual National Association of Specialty Pharmacy annual meeting shed light on the significant role these caregivers play in patient care.
4. Ofatumumab Demonstrates Efficacy in Relapsing Multiple Sclerosis
Two phase 3 studies showed that ofatumumab was superior to teriflunomide (Aubagio) in patients with relapsing forms of multiple sclerosis.
3. Certain BRAF Mutations in Colorectal Cancer May Respond to Anti-EGFR Therapy
Patients with metastatic colorectal cancer harboring certain non-V600 BRAF mutations may benefit from anti-EGFR treatment.
2. Novel Hemophilia A Treatment Method Sees Early Success
New approach involves treating patients with a high dose factor VIII concentrates along with emicizumab, a modification of the standard immune tolerance induction.
1. FDA OKs Pembrolizumab/Lenvatinib Combo for Advanced Endometrial Carcinoma
The FDA approval of pembrolizumab plus lenvatinib for this new indication is the first under a new international collaboration with Australia and Canada.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
Effectively Managing Immunizations in the Long-Term Care SettingSeptember 18th 2025
Creating a Culture of Quality in Fast-Melt Tablet DevelopmentSeptember 18th 2025
Advise Patients About Self-Care Measures to Treat Mild to Moderate GI IssuesSeptember 18th 2025
